Erasca, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jonathan E. Lim
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10835 Road to the Cure San Diego CA United States of America 92121
- IPO Date
- Jul 16, 2021
- CIK
- 0001761918
- Website
- erasca.com
- Similar Companies
- Business
- Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies targeting RAS/MAPK pathway-driven cancers, which affect approximately 30% of human cancers; its pipeline includes naporafenib, a pan-RAF inhibitor for NRAS-mutant melanoma and RAS Q61X solid tumors studied in over 600 patients; ERAS-007, an oral ERK1/2 inhibitor for colorectal cancer, non-small cell lung cancer, and advanced gastrointestinal malignancies; ERAS-601, an oral SHP2 inhibitor for advanced solid tumors; ERAS-0015, a pan-RAS molecular glue evaluated in Phase 1 AURAS-1 trial for RAS-mutant solid tumors following FDA IND clearance in May 2025 and recent U.S. composition-of-matter patent issuance; ERAS-4001, a pan-KRAS inhibitor with FDA IND clearance for (K)RAS-mutant solid tumors; and ERAS-801, a CNS-penetrant EGFR inhibitor for recurrent glioblastoma multiforme, alongside a bispecific antibody targeting wildtype EGFR overexpression in head and neck squamous cell carcinoma and colorectal cancer. The company pursues three strategies: targeting upstream/downstream RAS/MAPK nodes, RAS directly, and resistance escape routes, with programs in Phase 1/2 trials including HERKULES-3 for ERAS-007 combinations, SEACRAFT-2 for naporafenib with Novartis' trametinib, and ongoing evaluations of monotherapy and combinations across multiple tumor types. Founded in 2018 and headquartered in San Diego, California, Erasca operates globally in clinical development, leveraging partnerships such as licensing agreements with Guangzhou Joyo Biotech for pan-RAS inhibitors, Medshine for pan-KRAS inhibitors, NiKang Therapeutics, Asana BioSciences, and Katmai Pharmaceuticals; recent developments encompass FDA IND approvals for ERAS-0015 and ERAS-4001 in 2025, preclinical data presentations at the AACR Annual Meeting in April 2025 highlighting superior potency, Q3 2025 business updates advancing the RAS franchise toward 2026 Phase 1 data readouts, and a cash position funding operations into late 2028.
Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. (NASDAQ:ERAS) on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; HBSS Investigating Intellectual Property Questions Regarding Lead Asset
Erasca to Present at the Jefferies Global Healthcare Conference
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript